Discover how novel therapies and expert consensus on the KDIGO framework are revolutionizing IgAN management to slow disease progression.

Credit available for this activity expires: 10/13/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-iga-nephropathy-management-evolving-treatment-2026a10010le?ecd=bdc_podcast_libsyn_mscpedu

ADCs are moving from the metastatic setting into curative-intent neoadjuvant and adjuvant lines of treatment. Are you ready?

Credit available for this activity expires: 10/5/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/antibody-drug-conjugate-therapy-early-breast-cancer-2026a10010lp?ecd=bdc_podcast_libsyn_mscpedu

Do you know who to test, when to test, and which biomarker test to use?

Credit available for this activity expires: 9/28/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/solving-alzheimers-disease-biomarker-puzzle-live-european-2026a1000y9g?ecd=bdc_podcast_libsyn_mscpedu

Do you know how to meet the challenges of treating uveitic macular edema?

Credit available for this activity expires: 9/28/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/advancing-uveitic-macular-edema-management-whats-new-2026a1000y92?ecd=bdc_podcast_libsyn_mscpedu

Move beyond supportive care with targeted therapies for immunoglobulin A nephropathy (IgAN) management.

Credit available for this activity expires: 09/24/2027
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patient-journeys-iga-nephropathy-optimizing-outcomes-patient-2026a1000xq5?ecd=bdc_podcast_libsyn_mscpedu

How can adjuvant therapy be optimally individualized? What tools and insights are required? Join us to learn more.

Credit available for this activity expires: 09/21/2027
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl?ecd=bdc_podcast_libsyn_mscpedu

Can CAR T-cell therapies achieve drug-free remission in severe refractory autoimmune diseases?

Credit available for this activity expires: 9/22/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patient-journey-severe-refractory-autoimmune-rheumatic-2026a1000xbu?ecd=bdc_podcast_libsyn_mscpedu

Are you up to speed on the latest updates on molecular-guided therapies in HR-positive/HER2-negative metastatic breast cancer (MBC)? Join us to learn more.

Credit available for this activity expires: 9/18/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/translating-molecular-insights-practice-hr-positive-her2-2026a1000y0g?ecd=bdc_podcast_libsyn_mscpedu